Juno Biomedical, Inc.

A more effective and safer bioelectric stroke treatment dev...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

For all the incredible breakthroughs technology has brought to the world of medicine, stroke treatment is one area that’s been left behind - until now.

It can also be implemented months after a stroke, instead of only immediately after as with other options.

With key support secured and non-clinical trials complete, the time has come to move forward with clinical trials - and to get stroke victims back to independence!

What a heart attack is to the heart, a stroke is to the brain.  What starts with poor diet, lack of exercise, or even just a genetic predisposition leads to the formation of a clot - creating a blockage of artery and cutting off blood and oxygen to the brain.  This causes cells and parts the brain itself to die, which leaves behind disfigurement, loss of mobility, and loss of specific bodily movement in patients.  Stroke is without a doubt a terrible affliction, and one that so many suffer from.  It remains the #1 cause of long-term disability in the US; and as technology has us leading increasingly sedentary lifestyles, is only becoming more common.  Furthermore, increases in average human life expectancy means brains are living longer too - leading to more occurrences.


For as debilitating as strokes are to sufferers and their loved ones, an underwhelming status quo in treatment is making the situation even more dire.  The tissue plasminogen activator (tPA) protein, which is the current “Gold Standard” stroke treatment, effectively treats only around 2% of stroke survivors - and leaves as many as 52% with permanent long-term disability.  Now, though, we do know that stem cell-based therapies, specifically exogenous cell transplant, can return some function after an ischemic stroke.  However, these methods are severely limited by a number of different factors, including:

Despite the presence of these drawbacks, we’re forced to deal with them to a certain extent; pharmaceuticals alone cannot repair damaged neurological tissue. Regenerative medicine seeks to bridge this gap, essentially offering a cure by reversing tissue damage.  The medical community has reached a consensus that new cells must be in place at the site of the damage, either by recruiting with electric currents or stem cell transplants.  The use of regenerative medicine is trending across the medical landscape, and especially in our case -  as people continue to search for the “holy grail” ability to repair damaged brain tissue.  Our brain is an electric organ - and we’re starting to realize we need to treat it with a far more integrated approach.  Now, all that’s needed is a breakthrough technology that bridges these efforts to the next level.


There’s a substantial market and medical need for therapies that do more than just treat symptoms; and at Juno Biomedical, Inc. we’re taking full advantage.  Our newest innovation, CELLTech™, offers a way to repair damaged neurological tissue without the need for exogenous stem cell transplantations.  It’s a wearable neuromodulation device with the ability to selectively guide stem cells to damaged tissue.  The key to the CELLTech™ solution is the careful refinement of microcurrents - which, after administration, draw new cells to the ischemic stroke region.

Source: http://www.the-scientist.com/?articles.view/articleNo/44097/title/Brain-Gain/

We’re helping patients and medical professionals alike fly past the common hurdles associated with cell transplant.  Based on successful animal and clinical studies, applied electric currents deliver all the benefits of traditional cell-based therapies - and then some.  This starts with the potential to return significant motor function to even the most severely disabled patients after an ischemic stroke.  Thanks to complete control over cells, almost 100% survivability of cells and established dosage requirements, the CELLTech™ process is considered to have minimal risk with high potential efficacy – while being more cost-effective long-term for the patient and family. And, with preliminary studies showing CELLTech™ will be both safe and effective for clinical use, it doesn’t have to be administered right away; in fact, it can be done months or up to years after a stroke.

CELLTech™’s simplified yet unique nature gives it a significantly shorter route to market than other lengthy regenerative therapies.  This makes our solution highly scalable from a global perspective - which is great news for both the medical community and our business interests.  Non-clinical trials and world-renowned research have already demonstrated applied electric currents are effective in regenerating mammalian brain tissue.  Ultimately, it also has the ability to develop for a number of additional indications related to brain injury.  Improved quality of life for many is now within reach!

The beauty of the CELLTech™ process lies in its naturalness.  Stem cells respond to electrical stimuli - and when a current is applied to a stem cell niche, a difference is created between that region and where you want the cells to go.  In our case, we use two very small electrodes - one where the stem cells reside and the other where the stroke occurred - to apply bioelectric micro-currents.  Wires connect the electrodes to a medical device that supplies electricity and monitors the currents, allowing us to literally guide the cells to the place they need to go.  Then, after the cells are quickly migrated through a process called cell electrotaxis – meaning a movement of cells in an electric field - the brain tissue starts to grow back.  To this end, we’re facilitating brain cell repair and enhancing recovery by amplifying the body’s normative healing process - and regenerating new neural connections between functional cells.

Here are just a few of the features and benefits that makes CELLTech™ truly revolutionary:

Unlike other therapies, which need to take place the same day of the stroke, CELLTech™ can be implemented 30-120 days after a stroke or even into the chronic stage, up to years after a stroke.

Applied electric currents can improve motor functions by at least 30%.  For many, this is the difference between walking and being in a wheelchair.

Cells are migrated through electricity, not through traditional extraction or transplant methods.  Additionally, CELLTech™ therapy has an “off switch” and can be terminated at any time if the patient has undesirable side effects.

There are fewer restrictions when it comes to who can use CELLTech™.

CELLTech™ is less costly to implement than other solutions - so we’re able to pass significant savings along to the patient’s family, who often incur most of the cost of stroke.  In fact, our solution reduces overall cost by up to two-thirds.

The patient, their family members, and medical professionals can seamlessly monitor patient health and treatment response with our real-time monitoring feature.

The hard work hasn’t stopped since the moment we opened for business in 2014.  After securing valuable intellectual property assets late the following year, we continued optimizing and developing the CELLTech™ device - and eventually completed all high-level requirements for its specification documentation.  Now, as we sit on the precipice of clinical trials, we reflect back on some of the more notable accomplishments that allowed us to arrive at this point:

Clinical prototype design.  CELLTech™ clinical prototype software architecture is now complete.  With it, we’ve demonstrated embedded signal generation in the appropriate frequency and duration we want - and also have the ability to alter the commands as needed. We additionally have a complete strategic roadmap to finalize the hardware components.

Gaining medical community support.  We’ve spoken with over 15 respected neurologists and neurosurgeons - and 100% of them fully accept our technology and are anxious to use it.  We’ve also enjoyed significant positive press, on outlets like Yahoo Finance, NBC, and MarketWatch.

IP portfolio secured.  We have secured the exclusive worldwide license to multiple patents and patent applications for our technology, with an issued patent in the US, and patent applications based on the issued patent in the EU and in China.

Key partnerships aligned.  We’ve entered into a key partnership with Promenade Software, Inc. - a company that’s developed several HIPAA-compliant medical devices.

Garnering investor attention.  On the fundraising front, a number of firms, Angel groups, family trusts and individuals are expressing interest in investing.

Interested in learning more about Juno Biomedical, the investment opportunity, and what we have in store for the future?  Don’t forget to request access to the private side of this profile!

Juno Biomedical was founded by CEO Trisha Pfluger while she was working on her Ph.D. in the summer of 2014.  It was the result of a 15-year vision - one that began with her battling with her own neurological condition for 4 years.  Trisha realized that though the ability to repair brain tissue did in fact exist, the business end of the equation was not fulfilled; and because of it, no usable solution existed.  The result was Juno Biomedical, Inc. and CELLTech™ - and to this day, she maintains full responsibility over business development strategy, fundraising, and partnerships.  A versatile background in both clinical sciences and research science and entrepreneurship make her the ideal individual to serve as CEO.  She’s published top-level research on cell electrotaxis in Nature, and has been central in a number of other projects at places like Shriner’s and the California Primate Center.

The Juno Biomedical, Inc. team is rounded by these four highly-qualified executives:

Mike Bellon, CTO - For nearly two decades, Mike has played key roles with F500 companies in Silicon Valley, accounting for over $30 million in sales.  He’s a respected systems engineer whose inventions have led to breakthroughs in data analysis, the IoT, and other areas.  As CTO, he’s fully responsible for setting and implementing the strategy behind CELLTech’s development.

Dr. Davit Mrelashvili, CMO - As a board certified neurologist, Davit has contributed to key clinical research involving MS and stroke patients.  He’s also a Key Opinion Leader and advisor for big pharma and MedTech giants, including Pfizer and Bayer.  His duties as Chief Medical Officer include establishing clinical trial sites and designing clinical protocol.

Wayne Pfluger, Treasurer - After working as an accountant for various corporations and startups, Wayne began a 23-year career as General Accounting Supervisor with Solvay.  Also serving as our Controller, he’s in charge of accounting, payroll, and taxes.

The CELLTech Advantage from Trisha Marie Pfluger on Vimeo.


Juno also relies heavily on the formidable expertise of our Board of Advisors.  Members include:

  • Dr. Allan Bernstein, Chair (neurology diagnosis and management, clinical trials);
  • Dr. Souvik Sen (neurology, specifically acute stroke treatment and prevention);
  • Dr. Jan Nolta (stem cells, regenerative therapies, clinical research);
  • Dr. Carolyn Rynard (drug, device, and biologic regulations worldwide);
  • Dr. Erwin Mangubat (functional neurosurgery);
  • Dr. Edward McKenna (entrepreneurial medicine);
  • Nola Masterson (global executive and board veteran).

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.co platform

Copyright © 2017 Startups.co. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.

// //